secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001193125-22-279720
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics Q3 net loss $13.4M; cash $116.6M, runway to Q1 2025
--------------------------------------------------------------------------

- Net loss of $13.4M ($0.44/share) vs $9.7M in Q3 2021; R&D expense $9.2M, up from $6.4M.
- Cash and marketable securities $116.6M as of Sept 30, 2022; expected to fund operations into Q1 2025.
- Suspends ImmunoPhage platform development to focus on TMAb platform for conditionally active antibodies.
- On track to submit IND for SNS-101 (anti-VISTA) in H1 2023; preclinical data presented at SITC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312522279720/0001193125-22-279720-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312522279720/d405639d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-279720

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer